Mode
Text Size
Log in / Sign up
N/A N=182 Randomized Single-blind Treatment

Staying Active With Arthritis: RCT of Physical Activity for Older Adults With Osteoarthritis and Hypertension

Osteoarthritis, Knee · Hypertension

Enrolled (actual)
182
Serious AEs
0.0%
Results posted
Jan 2018
Primary outcome: Primary: Performance of Lower Extremity Exercise at 25 Weeks — 46.84; 1.90 repetitions x sets/week — p=<.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
STAR Intervention (Behavioral); Attention-Control (Behavioral)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
University of Pittsburgh
Primary completion
Apr 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Performance of Lower Extremity Exercise at 25 Weeks
46.84; 1.90 <.0001 sig
PRIMARY
Participation in Fitness Walking at 25 Weeks
434.89; 409.98; 314.07; 321.44; 40.53; 46.69 0.130
PRIMARY
Objective Functional Status by the 6-minute Walk at 25 Weeks
465.46; 483.02 0.461
PRIMARY
Objective Functional Status by the Short Physical Performance Battery at 25 Weeks
11.29; 10.86 0.180
PRIMARY
Systolic Blood Pressure at 25 Weeks
120.33; 123.07 0.258
PRIMARY
Diastolic Blood Pressure at 25 Weeks
71.74; 73.10 0.416
PRIMARY
Performance of Lower Extremity Exercise at 52 Weeks
42.06; 3.14 <.0001 sig
PRIMARY
Participation in Fitness Walking at 52 Weeks
426.71; 408.30; 318.04; 321.01; 39.37; 47.97 0.272
PRIMARY
Objective Functional Status by the 6-minute Walk at 52 Weeks
480.29; 465.36 0.561
PRIMARY
Objective Functional Status by the Short Physical Performance Battery at 52 Weeks
11.20; 11.25 0.856
PRIMARY
Systolic Blood Pressure at 52 Weeks
122.54; 125.14 0.292
PRIMARY
Diastolic Blood Pressure at 52 Weeks
72.62; 74.06 0.396
SECONDARY
Subjective Functional Status at 25 Weeks
16.68; 18.30 0.424
SECONDARY
Quadriceps Strength at 25 Weeks
43.21; 41.88 0.586
SECONDARY
Pain by the Pain Subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index at 25 Weeks
4.25; 4.54 0.596
SECONDARY
Pain by the Bodily Pain Subscale of the Short Form-36v2 at 25 Weeks
59.65; 58.13 0.639
SECONDARY
Fatigue at 25 Weeks
2.49; 2.76 0.466
SECONDARY
Health-Related Quality of Life at 25 Weeks
53.92; 52.30; 43.10; 43.07 0.322
SECONDARY
Self-Efficacy at 25 Weeks
59.81; 58.37; 67.43; 60.20 0.710
SECONDARY
Arthritis Self-Efficacy at 25 Weeks
75.58; 67.38; 85.74; 85.90; 78.88; 77.66 0.005 sig
SECONDARY
Outcome Expectancy at 25 Weeks
72.79; 59.67; 77.14; 69.62 0.001 sig
SECONDARY
Subjective Functional Status at 52 Weeks
17.02; 17.51 0.816
SECONDARY
Quadriceps Strength at 52 Weeks
43.66; 43.33 0.895
SECONDARY
Pain by the Pain Subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index at 52 Weeks
4.09; 4.72 0.260
SECONDARY
Pain by the Bodily Pain Subscale of the Short Form-36v2 at 52 Weeks
59.73; 59.70 0.993
SECONDARY
Fatigue at 52 Weeks
2.97; 2.94 0.947
SECONDARY
Health-Related Quality of Life at 52 Weeks
53.18; 51.81; 42.10; 42.47 0.406
SECONDARY
Self-Efficacy at 52 Weeks
53.30; 53.05; 55.49; 51.00 0.950
SECONDARY
Arthritis Self-Efficacy at 52 Weeks
73.15; 69.44; 85.38; 87.75; 75.92; 75.23 0.219
SECONDARY
Outcome Expectancy at 52 Weeks
67.09; 55.86; 73.40; 67.93 0.008 sig

Summary

The purpose of the Staying Active with Arthritis (STAR) research study is to determine if a 6-month program will improve leg exercise, fitness walking, and clinical outcomes (function, blood pressure, leg strength, pain, fatigue, and health-related quality of life) in older adults with osteoarthritis of the knee and high blood pressure.

Eligibility Criteria

Inclusion Criteria

  • Age 50 years or older.
  • Is community dwelling.
  • Has osteoarthritis of the knee.
  • Has hypertension for which monotherapy or combination pharmacological treatment is prescribed.
  • Able to complete a behavioral run-in consisting of completing questionnaires, using a 7-day electronic-diary, and wearing an ActiGraph accelerometer at the waist for 7 days.
  • Has written permission to participate from the physician.

Exclusion Criteria

  • Reports currently doing lower extremity exercise => 2 times/week.
  • Reports currently fitness walking => 90 minutes/week.
  • Incapable of managing their own treatment regimen.
  • Does not have, or cannot use, a telephone or is unwilling to provide a telephone number.
  • Has received cortisone or Synvisc injections in the knee, angioplasty, stents, or a pacemaker in the past 6 months.
  • Reports unstable cardiovascular, pulmonary, or metabolic disease or signs and symptoms suggestive of cardiovascular, pulmonary, or metabolic disease that restrict activity.
  • Has resting systolic blood pressure => 160 mm Hg or diastolic blood pressure => 100 mm Hg.
  • Reports other conditions, such as osteoarthritis of the hip, spinal stenosis, inflammatory arthritis, foot drop, diabetes treated with insulin, or diabetic complications that may affect performance of lower extremity exercise and participation in fitness walking.
  • Reports current knee conditions, such as meniscus tears and knee ligament ruptures.
  • Reports major depression that may impact the ability to fully participate in this study.
  • Is scheduled to undergo a major surgical procedure in the next 13 months.
  • Is concurrently participating in a drug or psychoeducational trial that may confound, or be confounded by, participation in this study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01280903). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search